Modeling alcohol toxicity in human hepatocytes
Modeling alcohol toxicity in human hepatocytes
批准号:
10205948
负责人:
Ype Peter De Jong
金额:
$38.14万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-05 至 2024-06-30
关键词:
Alcoholic HepatitisAlcoholic Liver CirrhosisAlcoholic Liver DiseasesAlcoholsAnimalsBiological ModelsCell TransplantationCellsCessation of lifeCirrhosisComplexDiseaseEngineeringEngraftmentEnvironmental Risk FactorEthanolEthanol MetabolismEthanol toxicityFailureFatty LiverGenerationsGeneticGenetic Predisposition to DiseaseGenomicsGoalsHepatocyteHumanHuman GeneticsImmunodeficient MouseImpairmentIn VitroIndividualInjuryLentivirus VectorLiverLiver diseasesLiver parenchymaLong-Term EffectsModelingMusNatural regenerationOrganoidsOutcome StudyPatientsPhenotypePluripotent Stem CellsPositioning AttributePrimary carcinoma of the liver cellsProliferatingProtocols documentationResearchRodentRodent ModelRoleSourceSystemTechnologyTestingTherapeutic UsesToxic effectTransplantationUnited StatesVariantadvanced systemalcohol effectalcohol exposurealcohol misusealcohol responsebasedesignfeedinggenetic manipulationgenetic variantimprovedin vivoinduced pluripotent stem cellinsightliver cell proliferationliver injurymouse modeloverexpressionreconstitutionresponsespecies differencestem cell therapytool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Alcohol contributes to nearly half the liver related deaths in the United States, mostly from cirrhosis
and hepatocellular cancer. Even though large numbers of people misuse alcohol, only a small fraction
develops liver disease. A better understanding of the mechanisms that contribute to hepatocyte damage
from alcohol is clearly warranted.
Mouse models are one tool to further our understanding of the role of alcohol on hepatocytes.
However, in part due to species differences and because human genetic predispositions cannot be modeled
in mice, ethanol studies in mice have been of limited translational use. An alternative approach to study the
effects of alcohol on human hepatocytes are liver chimeric mice. These models are based on the
transplantation of primary human hepatocytes into immunodeficient mice with liver injury, after which the
human cells proliferate and repopulate the mouse liver parenchyma. There are many limitations with these
models, one of them being that only very healthy hepatocytes engraft. Hepatocytes from patients with
inflamed livers or cirrhosis generally fail to engraft, which has limited our ability to create disease-specific
chimeric models. Possible solutions to this problem would be to genetically manipulate primary hepatocytes
or to create chimeric mice with pluripotent stem cells. However, manipulating primary human cells has
remained challenging and pluripotent stem cells have largely failed to reconstitute liver chimeric models.
We have recently created protocols to efficiently engraft a liver chimeric model with induced
pluripotent stem cells or with primary cells that were genetically altered in culture These protocol leads to
chimeric animals in which the majority of the liver has been humanized. In addition we can isolate large
numbers of human hepatocytes from these mice to create primary human hepatocyte cultures that are
stable for months. These advances, combined with a new organoid system, provides us with unique tools to
study various hepatocyte responses to alcohol.
We here propose to combine these advances to test the effects of alcohol on human hepatocytes.
We will use both primary human hepatocytes and pluripotent stem cell-derived hepatocytes to establish
systems of alcohol toxicity in hepatocytes, and test a genetic variant that predisposes humans to develop
alcoholic hepatitis. In addition the new organoid technology will allow us to test the effects of alcohol on
hepatocyte regeneration.
At the completion of these studies we will have established systems with which the effects of long-
term alcohol toxicity on human hepatocytes can be modeled. These systems will further advance the
creation of patient-specific chimeric models for alcoholic liver disease, and may advance the use of stem
cell therapies for therapeutic use in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Hepatocyte and Discovery Core
-
批准号:10560532
-
项目类别:
-
资助金额:$40.06万
-
财政年份:2022
-
负责人:Ype Peter De Jong
-
依托单位:
Human Hepatocyte and Discovery Core
-
批准号:10333187
-
项目类别:
-
资助金额:$40.55万
-
财政年份:2022
-
负责人:Ype Peter De Jong
-
依托单位:
Modeling alcohol toxicity in human hepatocytes
-
批准号:10663192
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2019
-
负责人:Ype Peter De Jong
-
依托单位:
Modeling alcohol toxicity in human hepatocytes
-
批准号:10442515
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2019
-
负责人:Ype Peter De Jong
-
依托单位:
Modeling alcohol toxicity in human hepatocytes
-
批准号:10006500
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2019
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:9721569
-
项目类别:
-
资助金额:$70.88万
-
财政年份:2018
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:9756452
-
项目类别:
-
资助金额:$69.64万
-
财政年份:2018
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:10401846
-
项目类别:
-
资助金额:$72.97万
-
财政年份:2016
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:10615731
-
项目类别:
-
资助金额:$72.42万
-
财政年份:2016
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:9278274
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2016
-
负责人:Ype Peter De Jong
-
依托单位:
Enhancing immune regulation in gene therapy for hemophilia
-
批准号:10210504
-
项目类别:
-
资助金额:$76.13万
-
财政年份:2016
-
负责人:Ype Peter De Jong
-
依托单位:
The role of innate immune evasion in hepatitis C virus infection
-
批准号:8190282
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2011
-
负责人:Ype Peter De Jong
-
依托单位:
The role of innate immune evasion in hepatitis C virus infection
-
批准号:8323869
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2011
-
负责人:Ype Peter De Jong
-
依托单位:
The role of innate immune evasion in hepatitis C virus infection
-
批准号:8508936
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2011
-
负责人:Ype Peter De Jong
-
依托单位:
海外基金